(Q36806028)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Tetyana Nehrych

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sergii Moskovko

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Peter Turcani

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Ovidiu Bajenaru

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Thomas Berger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Tanja Hojs Fabjan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Alenka Horvat Ledinek

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Gábor Jakab

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Samuel Komoly

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Tetiana Kobys

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jörg Kraus

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Egon Kurča

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Theodoros Kyriakides

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L'ubomír Lisý

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Panayiotis Panayiotou

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Saša Šega Jazbec

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Larysa Sokolova

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Radomír Taláb

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Latchezar Traykov

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Karl Vass

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Norbert Vella

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Nataliya Voloshyná

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Eva Havrdová

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Franz Fazekas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

1 reference

1 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

published in

Frontiers in Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group

29 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Fingolimod is a potential novel therapy for multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

The alliance of sphingosine-1-phosphate and its receptors in immunity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Sphingosine-1-phosphate: an enigmatic signalling lipid

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Cost of multiple sclerosis in the Czech Republic: the COMS study.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640198

Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23641231

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23641231

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3389/FNEUR.2013.00010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

23641231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23641231%20AND%20SRC:MED&resulttype=core&format=json